Company Interview / How Cryosite is turning frozen assets into hot growth

Key points

Specialised focus on ultra‑frozen and cryogenic storage for advanced therapiesCapacity-led growth via a new Sydney warehouse, funded from operating cash flowStrong demand outlook tied to rapidly expanding cell and gene therapy markets

Andrew Kerr, Executive Director of Cryosite (ASX:CTE) outlines a strong FY26 trading update, with net profit reportedly rising 20% and revenue 18%, driven by capacity-led growth. Kerr characterises Cryosite as a specialist storage and logistics provider for clinical trial and biological products across the full temperature spectrum, from ambient to ultra-frozen and cryogenic levels at -80°C and -196°C. He highlights a niche in handling advanced therapies such as mRNA vaccines, cell and gene therapies and CAR‑T treatments, requiring specialised infrastructure and staff.

Kerr attributes current momentum to a strategic capacity expansion in western Sydney, where a second warehouse has effectively doubled storage capability. He stresses a disciplined, demand-led rollout of this new facility, aiming to tailor fit-outs to client requirements. In his view, strong operating cash flow supports capital expenditure without the need to raise fresh equity, which he sees as significant for a smaller ASX-listed company (ASX:CTE).

Looking ahead, Kerr expects robust tailwinds from accelerating adoption of cell and gene therapies, which he notes some market participants forecast to grow around 30% annually. He points to Nasdaq‑listed Cryoport ($CYRX) as a key global peer and sees Cryosite evolving from a domestic operator into an Asia‑Pacific and potentially global player over the next three to five years.